Compare BOF & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOF | XLO |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 49.8M |
| IPO Year | 2023 | 2021 |
| Metric | BOF | XLO |
|---|---|---|
| Price | $4.67 | $8.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 129.8K | 26.9K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,184,018.00 | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 258.20 | ★ 589.88 |
| 52 Week Low | $1.93 | $0.46 |
| 52 Week High | $4.95 | $9.30 |
| Indicator | BOF | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 69.03 | 63.66 |
| Support Level | $2.92 | $7.47 |
| Resistance Level | $4.86 | $8.97 |
| Average True Range (ATR) | 0.35 | 0.50 |
| MACD | 0.11 | 0.08 |
| Stochastic Oscillator | 86.43 | 79.80 |
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.